Food industry unites for the first time with biotech companies and hospitals to create solutions in the prevention of gestational diabetes
Led by Patia Europe, the hub of Spanish food companies, tech and biotechnology companies was presented on 14th November, the International Diabetes Day.
Gestational diabetes (GDM), which affects 10% of pregnancies in Spain, is one of the main health problems associated with pregnancy. It is characterized by carbohydrate intolerance, is diagnosed between the 24th and 26th week, and is associated with considerable risks to both the mother and the fetus. So, the challenge is for pregnant women to have access to better evidence of prevention, care, products and education on GDM.
One in two women with gestational diabetes will develop diabetes 10 years after childbirth. The fetus can have serious health problems such as malformations, respiratory failure, even fetal death. A baby born of a pregnancy with gestational diabetes has a 60% greater chance of developing obesity and type 2 diabetes in the future.
Left to right: Leire Mendizábal (PATIA Technical Director), Jaime Razkin (PATIA Marketing & operations), Ainara Arregui (ANGULAS AGUINAGA R+D Manager ), Nekane Larburu (VICOMTECH Senior Researcher), Goizane Lizarralde (OKIN R+D Director), Céline Corrignan (OKIN Sales director), Javier Escobal (INIT Group Innovation Director), Roberto Álvarez ( VICOMTECH Researcher), Ainhoa C. Angoitia (SENDABIO Research Director), Sara Arranz (AZTI Food & Health Senior Researcher).
Products in progress
The first achievement of this consortium is Patia’s genetic test for the early detection of gestational diabetes. It is a genetic test, named GDMpredict, which is a non-invasive, highly specific and sensitive test that determines the risk of developing gestational diabetes during pregnancy. It is a world novelty that allows the detection of gestational diabetes before pregnancy or in the first weeks, well before the current diagnosis which facilitates the prevention of serious complications that gestational diabetes can entail. The test has been developed together with the Biocruces Research Institute, Basque country, Spain.


The food industry is developing foods and supplements for prevention and non-pharmacological intervention.
Angulas Aguinaga sells mainly in Europe and Latin America and has successful collaborations in Asia as well, with an annual turnover of more than 160M. provides food proposals that help to prevent some of the most important health problems of the 21st century, such as type 2 diabetes or gestational diabetes. In this project, Angulas Aguinaga develops new surimi products based on fish protein with an improved nutritional profile to meet the needs of the target population: patients with diabetes. Its proposals are focused on offering solutions that incorporate fewer carbohydrates and encourage protein intake.


The alliance was presented by Céline Corrignan (OKIN), Jaime Razkin (PATIA) and Ainara Arregui (ANGULAS AGUINAGA)



Patia DIabetes
Latest posts by Patia DIabetes (see all)
- From gestational diabetes to type 2 - 10 November, 2020
- COVID-19 & Diabetes: the dangerous interaction of two pandemics - 24 June, 2020
- New Covid-19 features in DIABETESprevent app - 7 April, 2020

